6 Results Found

Advanced Search

Select all

Results per page

Select all

Article

13 Citations

4,030 Views

16 Pages

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Michele A. Kohli,
Michael Maschio,
Shannon Cartier,
Joaquin Mould-Quevedo and
Frank-Ulrich Fricke

Vaccines2022, 10(9), 1386;https://doi.org/10.3390/vaccines10091386

25 August 2022

Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research...

Full Article

Article

38 Citations

8,706 Views

17 Pages

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season

Stephen I. Pelton,
Victoria Divino,
Drishti Shah,
Joaquin Mould-Quevedo,
Mitch DeKoven,
Girishanthy Krishnarajah and
Maarten J. Postma

Vaccines2020, 8(3), 446;https://doi.org/10.3390/vaccines8030446

7 August 2020

The influenza-related disease burden is highest among the elderly. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent influenza vaccine (aTIV) compared to other egg-based influenza vaccines (high-dose trivalent (TIV-HD), qu...

Full Article

Review

11 Citations

6,664 Views

31 Pages

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Maarten Postma,
David Fisman,
Norberto Giglio,
Sergio Márquez-Peláez,
Van Hung Nguyen,
Andrea Pugliese,
Jesús Ruiz-Aragón,
Analia Urueña and
Joaquin Mould-Quevedo

Vaccines2023, 11(6), 1089;https://doi.org/10.3390/vaccines11061089

11 June 2023

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quad...

Full Article

Article

8 Citations

8,668 Views

17 Pages

Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50–64 Years, and At-Risk Adults Aged 19–64 Years

Min Joo Choi,
Gyeongseon Shin,
Daewon Kang,
Jae-Ok Lim,
Yun-Kyung Kim,
Won Suk Choi,
Jae-Won Yun,
Ji Yun Noh,
Joon Young Song and
Woo Joo Kim
+ 2 authors

Vaccines2022, 10(3), 445;https://doi.org/10.3390/vaccines10030445

14 March 2022

The high disease burden of influenza in elderly and chronically ill adults may be due to the suboptimal effectiveness and mismatch of the conventional trivalent influenza vaccine (TIV). This study evaluated the cost-effectiveness of quadrivalent (QIV...

Full Article

Article

5 Citations

3,046 Views

14 Pages

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada

Van Hung Nguyen and
Bertrand Roy

Vaccines2022, 10(8), 1257;https://doi.org/10.3390/vaccines10081257

4 August 2022

In Canada, approximately 12,000 people annually are hospitalized with influenza. While vaccination is the most effective method for reducing the burden of seasonal influenza, the propagation of vaccine virus strains in eggs can result in egg adaption...

Full Article

Article

22 Citations

5,169 Views

14 Pages

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment

Giovanna Elisa Calabrò,
Sara Boccalini,
Donatella Panatto,
Caterina Rizzo,
Maria Luisa Di Pietro,
Fasika Molla Abreha,
Marco Ajelli,
Daniela Amicizia,
Angela Bechini and
Irene Giacchetta
+ 7 authors

Int. J. Environ. Res. Public Health2022, 19(7), 4166;https://doi.org/10.3390/ijerph19074166

31 March 2022

Background. The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuva...

Full Article